Saturday, May 1, 2010
advertisement
ATC 2010 Preliminary Program Saturday, May 1, 2010 .......................................................................................... 5 Pre-Meeting Symposia ...................................................................................... 5 1. Essential Immunology for the Clinician – Full Day Session ....................... 5 2. Transplantation Immunology for Basic Scientists – Full Day Session ........ 7 3. Updates in Clinical Transplantation – Half Day Session ............................ 8 4. Pediatric Transplantation – Half Day Session ............................................ 9 5. Strategies to Expand the Liver Donor Pool .............................................. 10 6. Hot Topics in Infectious Disease: An Audience Response Program ........ 11 ATC 10th Anniversary Session......................................................................... 12 10th Anniversary Celebration, Opening Reception & Exhibits Open ................ 12 Poster Session I .............................................................................................. 12 Supporter Event .............................................................................................. 12 Sunday, May 2, 2010 .......................................................................................... 12 Sunrise Symposia ........................................................................................... 12 Th17 and Alloimmunity: An Update ............................................................. 12 Losing Memory: The Ageing Immune Response ......................................... 13 Impact of the Lung Allocation Score and Ex Vivo Donor Lung Management ..................................................................................................................... 13 Controversies in Management of HBV after Liver Transplantation .............. 13 Donor-Derived Infections: What Should We Be Doing? ............................... 14 Drug Monitoring in Distinct Patient Populations ........................................... 14 Moving Towards National Kidney Paired Donation: Challenges and Controversies............................................................................................... 14 Early Morning Workshops ............................................................................... 15 1. The Management of BK Virus Nephropathy ............................................ 15 2. Allocation in Small Bowel Transplantation: Comparing Apples and Oranges, The Current Prioritization Scheme! .............................................. 15 3. Endothelial Cell Crossmatch .................................................................... 15 4. Islet Transplantation: Update on the FDA/CIT Trial ................................. 15 5. Women’s Health after Transplantation ..................................................... 15 6. Single Incision Laparascopic Surgery (SILS) and Embryonic Natural Orifice Transumbilical Endoscopic Surgery (e-Notes) for Living Donor Nephrectomy ............................................................................................... 15 7. Molecular and Cellular Aspects of Cancer Pathogenesis After Transplantation ............................................................................................ 15 Break ............................................................................................................... 15 Joint Plenary and Award Session .................................................................... 15 State-of-the-Art Address .................................................................................. 16 Coffee Break ................................................................................................... 16 Midday Symposia ............................................................................................ 16 Learning From the “Near Miss:” Case Reviews of Living Liver Donors with Complex Complications ............................................................................... 16 Revisiting Old Friends: Management of Current Immunosuppression ......... 16 The Promise of Stem Cells .......................................................................... 17 Danger and the Allograft Response ............................................................. 17 1 ATC 2010 Preliminary Program Featured Symposium: Antibody-Mediated Rejection in Heart and Lung Transplantation ............................................................................................ 18 Featured Symposium: Implementing Vascularized Composite Allografts(VCA): A National Dialogue .......................................................... 18 Break ............................................................................................................... 18 Industry Luncheon ........................................................................................... 19 Break ............................................................................................................... 19 Allied Health Symposium I: Waiting for Transplant: Maintaining Patient Readiness ....................................................................................................... 19 Concurrent Sessions ....................................................................................... 19 Break ............................................................................................................... 19 Concurrent Sessions ....................................................................................... 19 Transplantation in Depth: Towards Tolerance in Transplantation: Who are the New Players? .................................................................................................. 19 Poster Session II ............................................................................................. 20 Industry Event ................................................................................................. 20 Monday, May 3, 2010 ......................................................................................... 20 Sunrise Symposia ........................................................................................... 20 Emerging Role of Tregs in Allograft Rejection and Tolerance ..................... 20 Life after Immunosuppressive Drugs: The Transplant Physician and the Tolerant Patient ........................................................................................... 21 Update on Hepatopulmonary Syndrome and Portopulmonary Hypertension ..................................................................................................................... 21 Banff 2009: New Concepts and Directions in Kidney Biopsy Interpretation and their Clinical Impact .............................................................................. 21 Ethical Dilemmas: Exploring the Boundaries of Risk for Transplant Recipients and Programs ............................................................................ 22 Cardiovascular Considerations in Solid Organ Transplantation ................... 22 Strategies for Successful Transplantation in the Complex Pediatric Candidate .................................................................................................... 23 Early Morning Workshops ............................................................................... 23 8. Complex Living Kidney Donors ................................................................ 23 9. Biomarkers and Vaccines for Infectious Disease ..................................... 23 10. Left Lobe Living Donor Liver Transplantation ........................................ 23 11. Hemodynamically Unstable Organ Donor: Approaches to Achieve Successful Organ Donation ......................................................................... 23 12. Combined Heart-Kidney Transplantation: Selecting the Right Candidate ..................................................................................................................... 23 13. Proteomic Approaches to Assessing Allograft Function and Injury ........ 23 14. Chemokines and the Allograft Response ............................................... 23 Break ............................................................................................................... 24 Joint Plenary and Award Session .................................................................... 24 State-of-the-Art Address .................................................................................. 24 Coffee Break ................................................................................................... 24 Midday Symposia ............................................................................................ 24 Transplant Jeopardy: Essential Infectious Disease ..................................... 24 2 ATC 2010 Preliminary Program Treatment of Hepatitis C in Liver Transplant Candidates and Recipients .... 24 Ischemia-Reperfusion .................................................................................. 25 Incompatible Kidney Transplantation: A Long-Term Solution? .................... 25 Featured Symposium: Pancreas Transplantation: Current Controversies ... 25 Belatacept Symposium ................................................................................ 26 Break ............................................................................................................... 26 Industry Luncheon ........................................................................................... 26 Break ............................................................................................................... 26 Concurrent Sessions ....................................................................................... 26 Break ............................................................................................................... 27 Transplantation In Depth: Calcineurin Inhibitors: Love ‘em or Leave ‘em? ...... 27 Concurrent Sessions ....................................................................................... 27 Poster Session III ............................................................................................ 28 AST Business Meeting .................................................................................... 28 Supporter Event .............................................................................................. 28 Tuesday, May 4, 2010 ........................................................................................ 28 Sunrise Symposia ........................................................................................... 28 Clinical Trials of Regulatory T Cells ............................................................. 28 Innovative Potential Solutions to Reduce Racial Disparities in Kidney Transplantation ............................................................................................ 28 Long-Term View of Pediatric Liver Transplantation ..................................... 29 Lack of Innovation in Donor Management: Where is the Science and What are the Obstacles? ....................................................................................... 29 Posttransplant Glomerular Diseases ........................................................... 29 Transplantation: Essentials of Financing and Governance .......................... 30 Early Morning Workshops ............................................................................... 30 15. HIV-HCV Liver Transplantation .............................................................. 30 16. Grant Writing Workshop for Basic Scientists ......................................... 30 17. Pulsatile Perfusion: Do Outcomes Justify the Costs? ............................ 30 18. Transplantation of the Highly Sensitized Thoracic Transplant Candidate: Foolishness or Necessity? ........................................................................... 30 19. Cellular Mediators of Chronic Rejection ................................................. 30 Break ............................................................................................................... 30 Joint Plenary and Award Session .................................................................... 31 Controversies in Transplantation: Can a Regulated System for Living Donor Incentives Work? ............................................................................................. 31 Coffee Break ................................................................................................... 31 Presidential Addresses.................................................................................... 31 AST and ASTS Awards ................................................................................... 31 Industry Luncheon ........................................................................................... 31 Break ............................................................................................................... 31 Concurrent Sessions ....................................................................................... 31 FDA Drug Development Symposium: Recent Approvals and Novel Approaches in Clinical Transplantation: Developing an Interactive Relationship Between Practice and Regulation .................................................................................. 32 Allied Health Symposium II: Health Care Reform: Erosion or Empowerment . 32 3 ATC 2010 Preliminary Program Break ............................................................................................................... 33 Concurrent Sessions ....................................................................................... 33 Poster Session IV ............................................................................................ 33 ASTS Business Meeting .................................................................................. 33 Industry Event ................................................................................................. 33 Wednesday, May 5, 2010 ................................................................................... 33 Sunrise Symposia ........................................................................................... 33 The Evolving Role of Biological Therapies in Transplant Immunosuppression ..................................................................................................................... 33 Xenotransplantation: Advances and Challenges ......................................... 34 Liver Allocation and Distribution: Reshuffling the Deck Chairs .................... 34 Tuberculosis Control in Transplantation ...................................................... 34 Early Morning Workshops ............................................................................... 35 20. Incorporating Molecular and Protein Biologic Technology into Daily Clinical Transplant Practice ......................................................................... 35 21. Generic Immunosuppressive Drugs: What to Do? ................................. 35 22. Virtual Crossmatching and Antibody Strength ....................................... 35 Break ............................................................................................................... 35 Joint Plenary and Award Session .................................................................... 35 State-of-the-Art/Keynote Address.................................................................... 35 Coffee Break ................................................................................................... 35 Concurrent Sessions ....................................................................................... 35 What’s Hot, What’s New .................................................................................. 36 4 ATC 2010 Preliminary Program Saturday, May 1, 2010 Pre-Meeting Symposia 1. Essential Immunology for the Clinician – Full Day Session Key Players of The Immune Response Chair: Lori West, MD, DPhil 8:00 am – 8:30 am How Does Rejection Occur? Fadi Lakkis, MD 8:30 am – 9:00 am Why T Cell Activation Matters: Applications to Human Transplant Recipients Stuart Knechtle, MD 9:00 am – 9:30 am B Cells and Plasma Cells: The Biology Behind the New Therapies Lori West, MD, DPhil 9:30 am – 10:00 am Regulating the Immune Response: Does this really happen in people? Jonathan Bromberg, MD, PhD 10:00 am – 10:30 am Coffee Break Effector Mechanisms of Allograft Injury Chair: Roslyn Mannon, MD 10:30 am – 11:00 am Transplant Injury: Fundamental Mechanisms and Clinical Relevance Anthony Jevnikar, MD 11:00 am – 11:30 am Overview of Innate Immunity and its Clinical Applications William Baldwin, MD, PhD 11:30 am – 12:00 pm Allograft Fibrosis: An Ends to the Means of Injury Roslyn Mannon, MD 5 ATC 2010 Preliminary Program 12:00 pm – 1:00 pm Lunch Break Clinical Applications of Basic Immunology—Part I Chair: Xian Li, MD, PhD 1:00 pm – 1:30 pm Understanding Immunosuppression: How the Drugs Really Work Martin Zand, MD, PhD 1:30 pm – 2:00 pm Targeting Non T Cell Pathways of Graft Injury: B, NK, Plasma Cells, & Monocytes Xian Li, MD, PhD 2:00 pm – 2:30 pm Update in Histocompatibility and Antibody Detection Elaine Reed, PhD 2:30 pm – 3:00 pm Transplant Tolerance: Fact or Fiction Kenneth Newell, MD, PhD 3:00 pm – 3:30 pm Coffee Break Clinical Applications of Basic Immunology—Part II Chair: Michael Mengel, MD 3:30 pm – 4:00 pm Gene Expression: The Technique, The Molecules and their Application to Transplantation Michael Mengel, MD 4:00 pm – 4:30 pm Immune Monitoring: From Bench to Bedside? Nader Najafian, MD 4:30 pm – 5:00 pm Responding to Viral Infection: Mechanisms and Consequences for Recipient Immunity and Allograft Injury Atul Humar, MD, MSc 6 ATC 2010 Preliminary Program 2. Transplantation Immunology for Basic Scientists – Full Day Session Update on the Role of Costimulatory Pathways in Transplantation Rejection and Tolerance Chairs: Allan Kirk, MD, PhD and Xian Li, MD, PhD 8:00 am – 8:30 am Role of Costimulatory Pathways in Regulating Alloimmune Responses: An Overview of Emerging Concepts Allan Kirk, MD, PhD 8:30 am – 9:00 am Co-Inhibitory Molecules Nader Najafian, MD 9:00 am – 9:30 am Costimulatory Signal Requirements of Memory T Cells Laurence Turka, MD 9:30 am – 10:00 am Role of Costimulatory Pathways in Th Differentiation and Induction of Foxp3+ Tregs TBD 10:00 am – 10:30 am Coffee Break Role of B Cells, Antibodies and Complement in Alloimmunity Chairs: Paul Terasaki, PhD and Geetha Chalasani, MBBS 10:30 am – 11:00 am Missing Self-Recognition and B Cell Tolerance David Nemazee, PhD 11:00 am – 11:30 am Mouse Models for Defining the Role of B Cells in Transplantation Rejection and Tolerance Anita Chong, PhD 11:30 am – 12:00 pm Antibodies and Complement in Allograft Rejection Robert Colvin, MD 12:00 pm – 12:30 pm Novel Treatment Strategies for Acute Humoral Rejection: Targeting B Cells, Plasma Cells and Complement Ali Naji, MD 7 ATC 2010 Preliminary Program 12:30 pm – 1:00 pm Lunch Break Cellular and Humoral Innate Immune Response to Alloantigens Chairs: Jerzy Kupiec-Weglinski, MD, PhD and Maria Luisa Alegre, MD, PhD 1:00 pm – 1:30 pm Innate Immune Response to Alloantigen: An Overview Robert Fairchild, PhD 1:30 pm – 2:00 pm NK Cells in Rejection and Tolerance Joren Madsen, MD, DPhil 2:00 pm – 2:30 pm Immunomodulatory Capacity of DCs Adrian Morelli, MD, PhD 2:30 pm – 3:00 pm Emerging Role of Complements in Alloimmunity Peter Heeger, MD 3:00 pm – 3:30 pm Coffee Break Advances in Stem Cell Biology Chairs: Nicholas Zavazava, MD, PhD and Reza Abdi, MD 3:30 pm – 4:00 pm Pluripotent Stem Cells Kevin Eggan, PhD 4:00 pm – 4:30 pm Therapeutic Use of Hematopoietic Stem Cells Megan Sykes, MD 4:30 pm – 5:00 pm Stem Cells and Clinical Trials in Transplantation Nicholas Zavazava , MD, PhD 3. Updates in Clinical Transplantation – Half Day Session Chairs: Christopher Marsh, MD and Donald Hricik, MD Outcomes of Recent Clinical Trials 8:00 am – 8:30 am Designing Future Clinical Trials: Lessons from the Past 8 ATC 2010 Preliminary Program Herwig-Ulf Meier-Kriesche, MD 8:30 am – 9:00 am Recent Trials: Kidney Transplantation Stephen Tomlanovich, MD 9:00 am – 9:30 am Recent Trials: Cardiothoracic Transplantation Josef Stehlik, MD 9:30 am – 10:00 am Recent Trials: Liver Transplantation Sandy Feng, MD, PhD 10:00 am – 10:30 am Coffee Break Antibodies and Transplantation 10:30 am – 11:00 am Which Transplant Candidate Should Not Be Desensitized? James Gloor, MD 11:00 am – 11:30 am New Therapies for Dealing with Antibodies: Proteasome Inhibitors E. Steve Woodle, MD 11:30 am – 12:00 pm New Therapies for Dealing with Antibodies: Complement Inhibition Mark Stegall, MD 12:00 pm – 12:30 pm Clinical Significance of Non-HLA Antibodies Elaine Reed, PhD 4. Pediatric Transplantation – Half Day Session This session is co-sponsored by the IPTA Minimizing Immunosuppression in the Current Era Chairs: Edson Franco, MD and Lars Pape, MD, PhD 8:00 am – 8:30 am Steroid-free IS: Does it Really Make a Difference? Minnie Sarwal, MD, PhD 8:30 am – 9:00 am Liver Transplantation and Immunosuppression: Why give it anyway? Sandy Feng, MD, PhD 9 ATC 2010 Preliminary Program 9:00 am – 9:30 am Can CNI’s Truly be Avoided in Pediatric Solid Organ Transplantation? William Harmon, MD 9:30 am – 10:00 am Minimizing Immunosuppression in Thoracic Transplantation: Risky Business? Steven Webber, MBChB, MRCP 10:00 am – 10:30 am Coffee Break Are We Ready for Donation after Cardiac Death in Children? Chairs: Anne Dipchand, MD and John Magee, MD 10:30 am – 11:00 am DCD in the Pediatric Population: Experience and Outcomes Sonny Dhanani, MD 11:00 am – 11:30 am Establishing a DCD Program at a Children’s Hospital Susan Bratton 11:30 am – 12:00 pm Ethical Issues James Bernat, MD 5. Strategies to Expand the Liver Donor Pool This is an audience response system session. Technical Variant Grafts Chairs: James Trotter, MD and Julie Heimbach, MD 1:00 pm – 1:30 pm Right-Left Split: Is There Room to Grow? Abhinav Humar, MD 1:30 pm – 2:00 pm Impact of the Left Lobe Living Donor Graft Charles Miller, MD 2:00 pm – 2:30 pm Split Liver Transplantation: Effect on Waitlist and Future Opportunities Xavier Rogiers, MD, PhD 2:30 pm – 3:00 pm Pediatric Living Donor Liver Transplantation: Past, Present and Future Jean Emond, MD 10 ATC 2010 Preliminary Program Expanded Criteria Donors Chairs: Shawn Pelletier, MD and James Eason, MD 3:00 pm – 3:30 pm DCD Liver Transplantation: Utility, Function and Future David Foley, MD 3:30 pm – 4:00 pm Donor Age and Steatosis: Are there Limits? Pierre-Alain Clavien, MD, PhD 4:00 pm – 4:30 pm Virally Infected Donors: HCV, HBV, HTLV Lewis Teperman, MD 4:30 pm – 5:00 pm Risk and Reward: Are there Ethical Limits to Expanding the Pool? Richard Freeman, MD 6. Hot Topics in Infectious Disease: An Audience Response Program This is an audience response system session. Chairs: Jay Alan Fishman, MD and Emily Blumberg, MD 1:00 pm – 1:30 pm Diagnosis and Management of EBV/PTLD Michael Green, MD, MPH 1:30 pm – 2:00 pm The “High Risk” Recipient: Multi Drug Resistant Pathogens Shirish Huprikar, MD 2:00 pm – 2:30 pm Aspergillosis: Still Here—Diagnosis and Treatment Bernard Kubak, MD, PhD 2:30 pm – 3:00 pm Cryptococcus: Choosing Therapies Nina Singh, MD 3:00 pm – 3:30 pm You’re going where?!! Travel Advice Camille Kotton, MD 3:30 pm – 4:00 pm Non-Tuberculous Mycobacteria (MOTT) Karen Doucette, MD 4:00 pm – 4:30 pm BK Nephropathy: What’s New? Hans Hirsch, MD, MSc 4:30 pm – 5:00 pm Vaccination of Transplant Patients 11 ATC 2010 Preliminary Program Deepali Kumar, MD ATC 10th Anniversary Session Chairs: John Lake, MD and Ronald Busuttil, MD, PhD 5:15 pm – 5:30 pm 10 Years of ATC: Reforming Clinical Management Abraham Shaked, MD, PhD 5:30 pm – 5:45 pm 10 Years of ATC: Reforming Scientific Thinking Laurence Turka, MD 5:45 pm – 6:00 pm American Journal of Transplantation: 10 Years in Review Philip Halloran, MD, PhD, OC, FRSC 10th Anniversary Celebration, Opening Reception & Exhibits Open 6:00 pm – 8:00 pm Poster Session I 6:00 pm – 8:00 pm Supporter Event 8:00 pm Sunday, May 2, 2010 Sunrise Symposia Th17 and Alloimmunity: An Update Chairs: William Burlingham, PhD and TBD 7:00 am – 7:25 am Th17 in Allograft Tolerance and Rejection David Wilkes, MD 7:25 am – 7:50 am Th17 Cell Biology D. Keith Bishop, PhD 12 ATC 2010 Preliminary Program 7:50 am – 8:15 am Plasticity of Treg Lineages and Its Implication in Transplantation TBD Losing Memory: The Ageing Immune Response Chairs: Johann Pratschke, MD, PhD and Xian Li, MD, PhD 7:00 am – 7:25 am Clinical Consequences of Increasing Donor and Recipient Age Stefan Tullius, MD, PhD 7:25 am – 7:50 am Age-Dependent Changes of the Alloimmune Response Daniel Goldstein, MD 7:50 am – 8:15 am Age, Telomere Dependent and Telomere Independent Senescence Anette Melk, MD, PhD Impact of the Lung Allocation Score and Ex Vivo Donor Lung Management Chairs: Robert Love, MD and Martin Zamora, MD 7:00 am – 7:25 am Optimal Selection of Lung Transplant Recipients: What have we learned in the last 20 years? Cynthia Gries, MD, MSc 7:25 am – 7:50 am Impact of LAS on Wait List Survival and Posttransplant Outcomes Edward Garrity, Jr., MD, MBA 7:50 am – 8:15 am Present and Future of DCD in Lung Transplantation Robert Love, MD Controversies in Management of HBV after Liver Transplantation Audience Response System Chairs: Timothy Pruett, MD and Jeffrey Crippin, MD 7:00 am – 7:25 am Overview of HBV and Liver Transplantation: Why is there a controversy? Robert Gish, MD 7:25 am – 7:50 am Evidence for Chronic Maintenance Administration of HBlg 13 ATC 2010 Preliminary Program Robert Perrillo, MD 7:50 am – 8:15 am Evidence for withdrawal or avoidance of HBlg Administration Edward Gane, MD Donor-Derived Infections: What Should We Be Doing? Chairs: Michael Ison, MD, MS and Francis Delmonico, MD 7:00 am – 7:25 am How well are we Assessing Infectious Risk in Donors? Daniel Lebovitz, MBBS 7:25 am – 7:50 am CDC Update Matthew Kuehnert, MD 7:50 am – 8:15 am Should We Use Organs from HIV positive or HCV Infected Donors? Michael Ison, MD, MS Drug Monitoring in Distinct Patient Populations Chairs: Eric Tichy, PharmD and Steven Gabardi, PharmD, BCPS 7:00 am – 7:25 am Pharmacokinetic Differences Between Transplant Recipients of Different Ethnicities Fatemeh Akhlaghi, PharmD, PhD 7:25 am – 7:50 am Genomic Factors that Influence Metabolism of Common Immunosuppressants Pamala Jacobson, PharmD 7:50 am – 8:15 am Therapeutic Drug Monitoring in the HIV-positive Transplant Recipients: An Evaluation of the Impact of HAART Therapy on Maintenance Immunosuppression Christin Rogers, PharmD Moving Towards National Kidney Paired Donation: Challenges and Controversies Audience Response System Chairs: Ajay Israni, MD, MS and Michael Rees, MD, PhD 7:00 am – 7:25 am Update on the UNOS KPD Pilot and Program John Friedewald, MD 14 ATC 2010 Preliminary Program 7:25 am – 7:50 am Challenges and Benefits of Collaboration in KPD Jeffrey Veale, MD 7:50 am – 8:15 am Options for Allocation of Non-Directed Donors to KPD Programs Dorry Segev, MD, PhD Early Morning Workshops 7:00 am – 8:15 am 1. The Management of BK Virus Nephropathy Moderators: Hans Hirsch, MD, MSc and Cinthia Drachenberg, MD 2. Allocation in Small Bowel Transplantation: Comparing Apples and Oranges, The Current Prioritization Scheme! Moderators: Jonathan Fryer, MD and Douglas Farmer, MD 3. Endothelial Cell Crossmatch Moderators: Elaine Reed, PhD and Kathryn Tinckam, MD, MMSc 4. Islet Transplantation: Update on the FDA/CIT Trial Moderators: Bernhard Hering, MD and Ali Naji, MD 5. Women’s Health after Transplantation Moderators: Dianne McKay, MD and Vincent Armenti, MD, PhD 6. Single Incision Laparascopic Surgery (SILS) and Embryonic Natural Orifice Transumbilical Endoscopic Surgery (e-Notes) for Living Donor Nephrectomy Moderators: Rolf Barth, MD and L. Thomas Chin, MD 7. Molecular and Cellular Aspects of Cancer Pathogenesis After Transplantation Chairs: Olivia Martinez, PhD and Edward Geissler, PhD Break 8:15 am – 8:30 am Joint Plenary and Award Session 8:30 am – 10:00 am 15 ATC 2010 Preliminary Program State-of-the-Art Address 10:00 am – 10:30 am Regulation of the CD8 T Cell Response Michael Bevan, PhD, FRS Coffee Break 10:30 am – 11:00 am Midday Symposia 11:00 am – 12:30 pm Learning From the “Near Miss:” Case Reviews of Living Liver Donors with Complex Complications Chairs: Igal Kam, MD and Nancy Ascher, MD, PhD 11:00 am – 11:15 am International Survey of “Near-Misses” in Living Liver Donors Elizabeth Pomfret, MD, PhD 11:15 am – 11:25 am Living Liver Donor with a Vascular Complication Chung-Mau Lo, MBBS, MS 11:25 am – 11:40 am Discussion Nancy Ascher, MD, PhD 11:40 am – 11:50 am Biliary Complication in a Living Liver Donor Chris Freise, MD 11:50 am – 12:05 pm Discussion Paul Greig, MD 12:05 pm – 12:15 pm Anesthetic Complication in a Living Liver Donor Jean Emond, MD 12:15 pm – 12:30 pm Discussion Jacques Belghiti, MD Revisiting Old Friends: Management of Current Immunosuppression Audience Response System Chairs: Donald Hricik, MD and John Gill, MD, MS 16 ATC 2010 Preliminary Program 11:00 am – 11:30 am Alemtuzumab: Sensible and Effective or Madness? John Pirsch, MD and Dixon Kaufman, MD, PhD 11:30 am – 12:00 pm Stopping Steroids: Does it make any sense yet? Robert Steiner, MD 12:00 pm – 12:30 pm What role is there for mTOR inhibitors in kidney transplantation? Barry Kahan, PhD, MD The Promise of Stem Cells Chairs: Nicholas Zavazava, MD, PhD and Anthony Jevnikar, MD 11:00 am – 11:30 am The Hematopoietic Stem Cell Niche TBD 11:30 am – 12:00 pm Stem Cells and the Pancreas Nicholas Zavazava, MD, PhD 12:00 pm – 12:30 pm Induced Pluripotent Stem Cells TBD Danger and the Allograft Response Chairs: TBD and Daniel Goldstein, MD 11:00 am – 11:20 am Cell Death and Danger Signals Kenneth Rock, MD 11:20 am – 11:40 am Heat Shock Proteins in the Danger Response Robert Fairchild, PhD 11:40 am – 12:00 pm Innate Immune Activation and Allograft Responses Fadi Lakkis, MD 12:00 pm – 12:20 pm Complement and the Allograft Response William Baldwin, MD, PhD 17 ATC 2010 Preliminary Program Featured Symposium: Antibody-Mediated Rejection in Heart and Lung Transplantation Session is co-sponsored with the International Society for Heart and Lung Transplantation (ISHLT) Chairs: Michael Fishbein, MD and Josef Stehlik, MD 11:00 am – 11:20 am Implications of Immunological Sensitization in Thoracic Transplantation Lori West, MD, DPhil 11:20 am – 11:40 am Pathogenesis and Histological Findings in AntibodyMediated Rejection of the Heart and Lung Allografts Rene Rodriguez, MD 11:40 am – 12:00 pm Clinical Presentation and Management of AntibodyMediated Rejection in Heart Transplantation A. G. Kfoury, MD 12:00 pm – 12:20 pm Clinical Presentation and Management of AntibodyMediated Rejection in Lung Transplantation Stuart Sweet, MD, PhD 12:20 pm – 12:30 pm Panel Discussion Featured Symposium: Implementing Vascularized Composite Allografts(VCA): A National Dialogue Chairs: Linda Cendales, MD and Jean Michel Dubernard,MD, PhD 11:00 am – 11 :30 am Government Oversight Elizabeth Ortiz-Rios, MD, MPH 11:30 am – 12:00 pm Donor Related Matters Susan Dunn, RN, BSN, MBA, CPTC 12:00 pm – 12:30 pm Getting a VCA Program Off the Ground: Challenges and Pitfalls Bohdan Pomahac, MD Break 12:30 pm – 12:45 pm 18 ATC 2010 Preliminary Program Industry Luncheon 12:45 pm – 2:00 pm Break 2:00 pm – 2:15 pm Allied Health Symposium I: Waiting for Transplant: Maintaining Patient Readiness This session is co-sponsored by the ITNS and NATCO Chairs: Catherine Garvey, RN, BA, CCTC and Beth Kallenborn, RN, BSN, CCTC 2:15 pm – 2:45 pm Managing Your Kidney Wait List in 2010 Robert Gaston, MD 2:45 pm – 3:15 pm Deceased Donor Kidney Wait List Management Tammy Sebers, RN, BSN, CNN 3:15 pm – 3:45 pm Paired Exchange Programs Marian Charlton, SRN, RN, CCTC 3:45 pm – 4:15 pm Desensitization Protocols Lynette Fix, BAN Concurrent Sessions 2:15 pm – 3:45 pm Break 3:45 pm – 4:00 pm Concurrent Sessions 4:00 pm – 5:30 pm Transplantation in Depth: Towards Tolerance in Transplantation: Who are the New Players? Adaptive Mechanisms Chairs: Sophie Brouard, PhD and Jonathan Bromberg, MD, PhD 2:15 pm – 2:45 pm T Cell Exhaustion E. John Wherry, PhD 19 ATC 2010 Preliminary Program 2:45 pm – 3:15 pm Tolerogenic Plasmacutoid Dendritic Cells Angus Thomson, PhD, DSc 3:15 pm – 3:45 pm Complement and Regulation of the Alloresponse Peter Heeger, MD 3:45 pm – 4:00 pm Break Innate Mechanisms Chairs: Peter Heeger, MD and Ronald Gill, PhD 4:00 pm – 4:22 pm NK Cell Tolerance Xian Li, MD, PhD 4:22 pm – 4:44 pm Lymph Node and Lymphatic Structures in Tolerance Jonathan Bromberg, MD, PhD 4:44 pm – 5:06 pm Where Are We Going From Here? A. Benedict Cosimi, MD Poster Session II 5:30 pm – 6:30 pm Industry Event 7:00 pm Monday, May 3, 2010 Sunrise Symposia 7:00 am – 8:15 am Emerging Role of Tregs in Allograft Rejection and Tolerance Chairs: Simon Robson, MD, PhD and Kathryn Wood, DPhil 7:00 am – 7:25 am Tregs and Immunological Self-Tolerance Simon Robson, MD, PhD 7:25 am – 7:50 am Foxp3: Role in Generation and Function of Tregs Kathryn Wood, DPhil 20 ATC 2010 Preliminary Program 7:50 am – 8:15 am Treg Therapy in the Clinic Terry Strom, MD Life after Immunosuppressive Drugs: The Transplant Physician and the Tolerant Patient Chairs: William Burlingham, PhD and Kenneth Newell, MD, PhD 7:00 am – 7:25 am Identification of Tolerant Liver Transplant Recipients Alberto Sanchez-Fueyo, MD, PhD 7:25 am – 7:50 am ITN/Newell Study of Tolerance Kidney Transplant Recipients in the US Kenneth Newell, MD, PhD 7:50 am – 8:15 am The Critical Role of the Transplant Patient in Tolerance Protocol and Assay Development William Burlingham, PhD Update on Hepatopulmonary Syndrome and Portopulmonary Hypertension Chairs: Michael Ramsay, MD and John Lake, MD 7:00 am – 7:25 am Natural History and Pathogenesis of Hepatopulmonary Syndrome and Portopulmonary Hypertension Susan Mandell, MD, PhD 7:25 am – 7:50 am Hepatopulmonary Syndrome: Selection of Transplant Candidates and Outcomes Karen Swanson, DO 7:50 am – 8:15 am Portopulmonary Hypertension: Selection of Liver Transplant Candidates and New Therapies Michael Krowka, MD Banff 2009: New Concepts and Directions in Kidney Biopsy Interpretation and their Clinical Impact Chairs: Ian Gibson, MD and Roslyn Mannon, MD 7:00 am – 7:25 am Update in Banff 2007 Interpretation for Kidney Allografts Lorraine Racusen, MD 21 ATC 2010 Preliminary Program 7:25 am – 7:50 am Adding Genotype to Phenotype: Will we have a Molecular Banff Classification? Michael Mengel, MD 7:50 am – 8:15 am Time 0 Kidney Biopsy: What Can We Learn from the Biopsy of the Donor Allograft? Thomas Mueller, MD, PhD Ethical Dilemmas: Exploring the Boundaries of Risk for Transplant Recipients and Programs Audience Response System Chairs: Alan Reed, MD and Stephen Bartlett, MD 7:00 am – 7:15 am What Do They Want From Me Anyway? Richard Howard, MD, PhD 7:15 am – 7:30 am A Study of Risk Richard Freeman, MD 7:30 am – 7:45 am Transplant Clinician and Candidate Perceptions of Risk and Specific Informed Consent for CDC-defined High Risk Donor Organs Elisa Gordon, PhD, MPH 7:45 am – 8:00 am Professional Obligations to the Transplant Tourist Benjamin Hippen, MD Cardiovascular Considerations in Solid Organ Transplantation Chairs: Teresa DeMarco, MD and Greg Knoll, MD 7:00 am – 7:25 am Cardiovascular Risk Assessment before Transplantation: Approaches and Controversies Krista Lentine, MD 7:25 am – 7:50 am Cardiovascular Effects of mTOR Inhibitors Howard Eisen, MD 7:50 am – 8:15 am Reducing Cardiovascular Events after Solid Organ Transplantation—What Works and What Does Not Bertram Kasiske, MD 22 ATC 2010 Preliminary Program Strategies for Successful Transplantation in the Complex Pediatric Candidate Chairs: Ruth McDonald, MD and Mark Benfield, MD 7:00 am – 7:25 am Focal Segmental Glomerulosclerosis (FSGS) in Pediatric Transplantation Mouin Seikaly, MD 7:25 am – 7:50 am Atypical Hemolytic Uremic Syndrome (HUS) Chantel Loirat, MD 7:50 am – 8:15 am Thrombophilia: How to Diagnose and Manage Peter Hoyer, MD Early Morning Workshops 7:00 am – 8:15 am 8. Complex Living Kidney Donors Moderators: Peter Reese, MD and Hassan Ibrahim, MD 9. Biomarkers and Vaccines for Infectious Disease Moderators: Raymund Razonable, MD and Deepali Kumar, MD 10. Left Lobe Living Donor Liver Transplantation Moderators: John Roberts, MD and Charles Miller, MD 11. Hemodynamically Unstable Organ Donor: Approaches to Achieve Successful Organ Donation Moderators: Craig Myrick, RN, CPTC and Jonathan Zaroff, MD 12. Combined Heart-Kidney Transplantation: Selecting the Right Candidate Moderators: Si Pham, MD, PhD and David Cohen, MD 13. Proteomic Approaches to Assessing Allograft Function and Injury Chairs: David Rush, MD and JM Campistol, MD, PhD 14. Chemokines and the Allograft Response Chairs: Reza Abdi, MD and Stuart Knechtle, MD, PhD 23 ATC 2010 Preliminary Program Break 8:15 am – 8:30 am Joint Plenary and Award Session 8:30 am – 10:00 am State-of-the-Art Address 10:00 am – 10:30 am Shimon Sakaguchi, MD, PhD Coffee Break 10:30 am – 11:00 am Midday Symposia 11:00 am – 12:30 am Transplant Jeopardy: Essential Infectious Disease Chair: Jay Alan Fishman, MD 11:00 am – 11:30 am From our studios in downtown San Diego: This is Transplant Jeopardy! 11:30 am – 11:50 am The Great Disappearing Act: Hepatitis C and Biliary Epithelium Jeffrey Crippin, MD 11:50 am – 12:10 pm HIV in Transplantation: Current Status Barbara Murphy, MD 12:10 pm – 12:30 pm CMV: Not so “Indirect” Effects Richard Freeman, MD Treatment of Hepatitis C in Liver Transplant Candidates and Recipients Chairs: Geoffrey McCaughan, PhD, MBBS and James Trotter, MD 11:00 am – 11:30 am Pre-Transplant Treatment of Hepatitis C: When and How Can it be Done Successfully? Gregory Everson, MD 24 ATC 2010 Preliminary Program 11:30 am – 12:00 pm Post-transplant HCV Treatment: What Can Patients Realistically Expect to Gain? Marina Berenguer, MD 12:00 pm – 12:30 pm Future HCV Therapies for Liver Transplant Candidates and Recipients: What Will be Available and When? Norah Terrault, MD, MPH Ischemia-Reperfusion Chairs: Stefan Tullius, MD, PhD and Steven Chadban, MD, PhD 11:00 am – 11:30 am Molecular Mediators of IRI Jerzy Kupiec-Weglinski, MD, PhD 11:30 am – 12:00 pm Role of Immune System in IRI Hamid Rabb, MD 12:00 pm – 12:30 pm Biomarkers of Ischemia Reperfusion Injury Joseph Bonventre, MD, PhD Incompatible Kidney Transplantation: A Long-Term Solution? Chairs: Stephen Tomlanovich, MD and James Gloor, MD 11:00 am – 11:30 am Long-Term Results of Live Donor PositiveCrossmatch Transplants Robert Montgomery, MD, DPhil 11:30 am – 12:00 pm Long-Term Results of ABO Incompatible Transplants Gunnar Tyden, MD 12:00 pm – 12:30 pm Long-Term Results of Deceased Donor Desensitization Ashley Vo, PharmD Featured Symposium: Pancreas Transplantation: Current Controversies Audience Response System Chairs: Jonathan Fridell, MD and Steven Paraskevas, MD, PhD 11:00 am – 11:25 am Pancreas-Kidney Transplantation: A Critical Evaluation of Outcomes Suphamai Bunnapradist, MD 25 ATC 2010 Preliminary Program 11:25 am – 11:50 am “SPK, PAK or KA?” Navigating the Options for Type 1 Diabetics Alexander Wiseman, MD 11:50 am – 12:15 pm Controversies in Allocation of Pancreas-Kidney Grafts Dixon Kaufman, MD, PhD 12:15 pm – 12:30 pm Panel Discussion Belatacept Symposium Chairs: Allan Kirk, MD, PhD and Herwig-Ulf Meier-Kriesche, MD 11:00 am – 11:20 am Current Status of the Clinical Trials on Belatacept in Solid Organ Transplantation Flavio Vincenti, MD 11:20 am – 11:40 am Past and Present Concerns of the Safety of Biologic Agents in Solid Organ Transplantation Lionel Rostaing 11:40 am – 12:00 pm Costimulation Blockade in the Clinic: Where Do We Go From Here? Mohamed Sayegh 12:00 pm – 12:30 pm Discussion Break 12:30 pm – 12:45 pm Industry Luncheon 12:45 pm – 2:00 pm Break 2:00 pm – 2:15 pm Concurrent Sessions 2:15 pm – 3:45 pm 26 ATC 2010 Preliminary Program Break 3:45 pm – 4:00 pm Transplantation In Depth: Calcineurin Inhibitors: Love ‘em or Leave ‘em? Audience Response System Chairs: Edward Cole, MD and Stephen Tomlanovich, MD 2:15 pm – 2:35 pm CNI Nephrotoxicity: Mechanistic Insights into Pathogenesis William Bennett, MD 2:35 pm – 2:55 pm Pathologic Criteria for CNI Nephrotoxicity: Are They Sufficient? Robert Colvin, MD 2:55 pm – 3:15 pm Is One CNI Superior to Another? Herwig-Ulf Meier-Kriesche, MD 3:15 pm – 3:35 pm Immunosuppressive Effects of CNI’s: Can They be Replaced? Allan Kirk, MD, PhD 3:35 pm – 3:55 pm Which Drug Classes are Best Suited to Replace CNI’s? Flavio Vincenti, MD 3:55 pm – 4:10 pm Break 4:10 pm – 5:00 pm Debate: CNI Toxicity: Reality or Myth? 4:10 pm – 4:30 pm Reality Jeremy Chapman, MD 4:30 pm – 4:50 pm Myth Arthur Matas, MD 4:50 pm – 5:00 pm Moderated Discussion Concurrent Sessions 4:00 pm – 5:30 pm 27 ATC 2010 Preliminary Program Poster Session III 5:30 pm – 6:30 pm AST Business Meeting 5:45 pm – 6:15 pm Supporter Event 7:00 pm Tuesday, May 4, 2010 Sunrise Symposia 7:00 am – 8:15 am Clinical Trials of Regulatory T Cells Chairs: Shuiping Jiang, PhD and David Game, MD, PhD 7:00 am – 7:25 am Clinical Trials of Regulatory T Cells for GVHD Robert Lechler, PhD 7:25 am – 7:50 am Clinical Trials of Tr1 Cells Manuela Battaglia, PhD 7:50 am – 8:15 am Clinical Trials of Double Negative Tregs for GVL Li Zhang, MD, MSc Innovative Potential Solutions to Reduce Racial Disparities in Kidney Transplantation Chairs: James Rodrigue, PhD and Lawrence Agodoa 7:00 am – 7:25 am Improving Transplant Education in Dialysis Centers to Reduce Health Disparities Amy Waterman, PhD 7:25 am – 7:50 am Increasing Living Donation in Africian Americans: Role of Patient Navigators Prabhakar Baliga, MD 28 ATC 2010 Preliminary Program 7:50 am – 8:15 am Old-Fashioned House Calls: Can they Reduce the Racial Disparity in Live Donor Kidney Transplantation? James Rodrigue, PhD Long-Term View of Pediatric Liver Transplantation Chairs: John Magee, MD and Nanda Kerkar, MD, MBBS 7:00 am – 7:25 am Health Status of the Long-Term Pediatric Survivor Vicky Ng, MD 7:25 am – 7:50 am Appearance of the Long-Term Allograft: A Cause for Concern? Stefan Hubscher, MD 7:50 am – 8:15 am Functional Outcomes and Quality of Liver for Pediatric Liver Transplant Recipients Estella Alonso, MD Lack of Innovation in Donor Management: Where is the Science and What are the Obstacles? Chairs: David Foley, MD and Steven Paraskevas, MD, PhD 7:00 am – 7:25 am Strategies for Donor Intervention Studies Rutger Ploeg, MD, PhD 7:25 am – 7:50 am Physiologic Targets in Donor Management and Intervention Trials Kenneth Wood, DO 7:50 am – 8:15 am Logistical and Ethical Challenges of Donor Intervention Trials Richard Freeman, MD Posttransplant Glomerular Diseases Chairs: Randal Detwiler, MD and Milagros Samaniego, MD 7:00 am – 7:25 am Risk Factors for Recurrent Glomerulopathies Mario Rubin, MD 7:25 am – 7:50 am Pathogenesis of Transplant Glomerulopathy Fernando Cosio, MD 29 ATC 2010 Preliminary Program 7:50 am – 8:15 am Hepatitis C-associated Glomerular Disease in Transplant Recipients Jose Morales, MD, PhD Transplantation: Essentials of Financing and Governance Chairs: Kenneth Andreoni, MD and Gene Ridolfi, RN, BA 7:00 am – 7:25 am Transplantation’s Governing History and Compliance Framework Jennifer Milton, BSN, MBA 7:25 am – 7:50 am Tools to Asses Patient Throughput, Market Comparison, and to Monitor Quality Indicators E. Janie Morrison-Fache, BHS 7:50 am – 8:15 am Financial Value of Transplantation Laura Murdock, MHA Early Morning Workshops 7:00 am – 8:15 am 15. HIV-HCV Liver Transplantation Moderators: Norah Terrault, MD, MPH and Kosh Agarwal, MD 16. Grant Writing Workshop for Basic Scientists Moderators: Robert Fairchild, PhD and Ronald Gill, PhD 17. Pulsatile Perfusion: Do Outcomes Justify the Costs? Moderators: Michael Hanaway, MD and Chris Freise, MD 18. Transplantation of the Highly Sensitized Thoracic Transplant Candidate: Foolishness or Necessity? Moderators: Duane Davis, MD and Steven Webber, MBChB, MRCP 19. Cellular Mediators of Chronic Rejection Moderators: Jessamyn Bagley, PhD and Maria Hernandez-Fuentes, MD, PhD Break 8:15 am – 8:30 am 30 ATC 2010 Preliminary Program Joint Plenary and Award Session 8:30 am – 9:45 am Controversies in Transplantation: Can a Regulated System for Living Donor Incentives Work? Chairs: Alan Reed, MD and Francis Delmonico, MD 9:45 am – 10:00 am The Iranian Model of Living Donor Incentives Nasrollah Ghahramani, MD, MS 10:00 am – 10:15 am The Philippine Model of Living Donor Incentives Benita Padilla, MD 10:15 am – 10:35 am Invited Commentary: US Implications Arthur Matas, MD and Gabriel Danovitch, MD 10:35 am – 10:45 am Discussion Coffee Break 10:45 am – 11:00 am Presidential Addresses 11:00 am – 12:00 pm AST and ASTS Awards 12:00 pm – 12:30 pm Industry Luncheon 12:45 pm – 2:00 pm Break 2:00 pm – 2:15 pm Concurrent Sessions 2:15 pm – 3:45 pm 31 ATC 2010 Preliminary Program FDA Drug Development Symposium: Recent Approvals and Novel Approaches in Clinical Transplantation: Developing an Interactive Relationship Between Practice and Regulation Chairs: Robert Gaston, MD and Stuart Knechtle, MD 2:15 pm – 2:30 pm Regulatory Challenges in Clinical Transplantation: The FDA Approach to Drug Development and its Application in Transplantation Joette Meyer 2:30 pm – 2:45 pm The Rationale Underlying FDA Transplant Product Approvals, Advisory Committee Meetings, and Safety Updates of the Past Year Ozlem Belen 2:45 pm – 3:00 pm Developing a Pathway Towards Effective Therapeutics for ABMR: A View from the Field James Gloor, MD 3:00 pm – 3:15 pm Developing a Pathway Towards Effective Therapeutics for ABMR: A View from the FDA and the Role of an Interactive Relationship between Practice and Regulation Patrick Archdeacon, MD 3:15 pm – 3:45 pm Panel Discussion Allied Health Symposium II: Health Care Reform: Erosion or Empowerment Chairs: Barry Friedman, RN, BSN, MBA and Deborah Ann Hoch, MSN, DNP© Audience Response System 3:00 pm – 3:30 pm Equal Treatment of the Candidate Patient in a Social Health Care Reform Model: Equality or Discrimination? John Gill, MD, MS 3:30 pm – 4:00 pm Health Care Reform: Erosion or Empowerment? Roger Evans, PhD 4:00 pm – 4:30 pm Identifying Risk: Does it Matter? 32 ATC 2010 Preliminary Program Michael Goldstein, MD Break 3:45 pm – 4:00 pm Concurrent Sessions 4:00 pm – 5:30 pm Poster Session IV 5:30 pm – 6:30 pm ASTS Business Meeting 5:45 – 6:45 pm Industry Event 7:00 pm Wednesday, May 5, 2010 Sunrise Symposia The Evolving Role of Biological Therapies in Transplant Immunosuppression Chairs: Rainer Oberbauer, MD, MSc and Greg Knoll, MD 7:00 am – 7:25 am New Targets, New Agents: An Overview of New Biologics Being Tested in Transplantation Mark Pescovitz, MD 7:25 am – 7:50 am CTLA4-lg and Belatacept: Bench to Bedside Development of a New Therapeutic Paradigm Christian Larsen, MD, PhD 7:50 am – 8:15 am Lessons Learned from Assessing the Safety of Biologics in Autoimmune Diseases Jeffrey Curtis, MD, MPH 33 ATC 2010 Preliminary Program Xenotransplantation: Advances and Challenges Chairs: Richard Pierson, III, MD and David Sachs, MD 7:00 am – 7:15 am Pig to Baboon Liver Transplantation David Cooper, MD, PhD 7:15 am – 7:30 am Molecular Targets of the non-Gal Immune Response Richard Pierson, III, MD 7:30 am – 7:45 am Progress in Controlling Coagulation Cascade Activation Simon Robson, MD, PhD 7:45 am – 8:00 am Recent Progress Toward Clinical Islet Xenotransplantation Pierre Gianello, MD, PhD 8:00 am – 8:15 am Discussion Liver Allocation and Distribution: Reshuffling the Deck Chairs Audience Response System Chairs: John Lake, MD and Elizabeth Pomfret, MD, PhD 7:00 am – 7:25 am Allocation for HCC: Too Much of a Good Thing? W. Kenneth Washburn, MD 7:25 am – 7:50 am Liver Distribution: New Ideas for an Old Problem John Roberts, MD 7:50 am – 8:15 am Survival Benefit Based Liver Allocation Doug Schaubel, PhD Tuberculosis Control in Transplantation Chairs: Martina Sester, PhD and Raymund Razonable, MD 7:00 am – 7:25 am Risk Factors for Tuberculosis in Transplant Recipients, Strategies for Prevention and Therapeutic Dilemmas Sandra Arend, MD, PhD 34 ATC 2010 Preliminary Program 7:25 am – 7:50 am Interferon-γ Release Assays (IGRA) in the Diagnosis of Latent and Active Tuberculosis Infection: Time to Abandon Skin-Testing? Martina Sester, PhD 7:50 am – 8:15 am Therapy of Latent and Active Tuberculosis Infection in Transplant Recipients and Candidates in Clinical Practice Patricia Munoz, MD Early Morning Workshops 7:00 am – 8:15 am 20. Incorporating Molecular and Protein Biologic Technology into Daily Clinical Transplant Practice Moderators: Robert Fisher, MD and Daniel Salomon, MD 21. Generic Immunosuppressive Drugs: What to Do? Moderators: Rita Alloway, PharmD, BCPS, FCCP and J. Harold Helderman, MD 22. Virtual Crossmatching and Antibody Strength Moderators: Howard Gebel, PhD and Peter Nickerson, MD Break 8:15 am – 8:30 am Joint Plenary and Award Session 8:30 am – 10:00 am State-of-the-Art/Keynote Address 10:00 am – 10:30 am Innate and Adaptive Immunity Richard Flavell, PhD, FRS Coffee Break 10:30 am – 10:45 am Concurrent Sessions 10:45 am – 12:15 pm 35 ATC 2010 Preliminary Program What’s Hot, What’s New Moderators: Robert Merion, MD and Joren Madsen, MD, DPhil 12:15 pm – 12:45 pm Basic Science James Markmann, MD, PhD 12:45 pm – 1:15 pm Clinical Science Stephen Tomlanovich, MD 36
